Published date: 2 November 2021

Withdrawn future opportunity


Approach to market date: 1 February 2022

Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

United Kingdom, Isle of Man, Channel Islands

Value of contract

£15,000,000

Procurement reference

CM/PHS/19/5583

Published date

2 November 2021

Approach to market date

1 February 2022

Contract start date

1 July 2022

Contract end date

30 June 2023

Procedure type

Open procedure (above threshold)

Any interested supplier may submit a tender in response to an opportunity notice.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

Yes

Contract is suitable for VCSEs?

No

Description

Icatibant, C1 Esterase products for the treatment of Hereditary Angioedema

More information

Previous notice about this procurement

NHS Framework Agreement for the supply of Icatibant & C1 Esterase products for the treatment of Hereditary Angioedema

  • Future opportunity
  • Published 13 December 2019, last edited 14 September 2021

Spend profile

This table displays the spend profile of the notice
Financial year Budget
2022/2023 £11,250,000
2023/2024 £3,750,000

About the buyer

Contact name

Karen Bell

Address

Commercial Medicines Unit - NHS England
2nd Floor, Rutland House
Runcorn
WA7 2ES
England

Email

karen.bell7@nhs.net